Agile therapeutics announces closing of $7.5 million public offering

Princeton, n.j., may 25, 2023 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx) ("agile therapeutics" or the "company"), a women's healthcare company, today announced the closing of its previously announced public offering of an aggregate of 1,896,286 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock warrants, at a public offering price of $3.9551 per share (or pre-funded warrant) and accompanying warrants. each share of common stock (or pre-funded warrant) was sold in the offering together with a series c-1 warrant to purchase one share of common stock at an exercise price of $3.69 per share and a series c-2 warrant to purchase one share of common stock at an exercise price of $3.69 per share. the series c-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the series c-2 warrants are exercisable immediately and will expire eighteen months from the date of issuance. total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.5 million.
AGRX Ratings Summary
AGRX Quant Ranking